Bluesight Launches ShortageCheck to Combat Critical Drug Supply issues
New platform offers hospitals up to 90-day warning of potential medication shortages, aiming to safeguard patient care and reduce operational strain.
A growing crisis in drug availability is prompting innovative solutions within the healthcare sector. Bluesight, a leading provider of hospital intelligence solutions, has launched ShortageCheck, a new technology designed to help health systems and hospitals proactively track, forecast, and manage drug inventories. The platform integrates real-time data, predictive analytics, and collaborative planning tools to address a pain point that has plagued the industry for years.
ShortageCheck aims to ensure uninterrupted access to essential medications for both caregivers and patients. The system monitors over 20 real-time market signals, including demand spikes and fulfillment delays, providing coverage for more than 2,500 acute care facilities across the United States.
The platform’s predictive capabilities are a key differentiator. ShortageCheck identifies early warning signs of potential drug shortages, offering a lead time of up to 90 days, with an average of 42 days. This allows healthcare institutions to adapt their inventory management strategies and mitigate potential disruptions. By assessing inventory levels, usage rates, and days-on-hand, the platform delivers in-depth insights into the potential impact of each shortage.
“Shortage management has been one of, if not the most critical, pain point for our customers over the last six years,” stated a company release. “When drug shortages hit without warning, it forces teams to scramble for alternatives, and patient care ultimately suffers.”
The launch of ShortageCheck is intended to alleviate these pressures. According to the release, the platform will preserve labor hours and costs during a period of rising drug prices, persistent staff shortages, and evolving Medicare reimbursement policies. It also enables organizations to evaluate risk, prioritize responses, and utilize built-in communication tools for seamless cross-team coordination and planning.
ShortageCheck is the latest addition to Bluesight’s suite of hospital intelligence solutions, which also includes CostCheck, KitCheck, 340BCheck, ControlCheck, and PrivacyPro. These tools collectively empower hospitals to expedite inventory restocking, reduce drug expenditure, streamline audit preparations, more effectively identify drug diversion, and improve patient privacy protections.
Bluesight further expanded its capabilities earlier this year, in January, with the acquisition of Protenus, a healthcare compliance analytics platform provider. This strategic move underscores the company’s commitment to providing thorough solutions for the evolving challenges facing the healthcare industry.
The introduction of ShortageCheck represents a meaningful step toward proactive drug shortage management, offering hospitals a vital tool to navigate a complex and increasingly volatile supply chain and ultimately prioritize patient well-being.
Why, Who, What, and How did it end?
Why: Bluesight launched ShortageCheck in response to a growing crisis of unpredictable drug shortages that negatively impact patient care and strain hospital operations.
who: Bluesight,a leading provider of hospital intelligence solutions,developed and launched the ShortageCheck platform. The platform is intended for use by health systems and hospitals across the United states, covering over 2,500 acute care facilities.
What: ShortageCheck is a new technology platform designed to proactively track, forecast, and manage drug inventories. It uses real-time data, predictive analytics, and collaborative tools to provide up to a 90-day warning of potential drug shortages.
**How did it end?:
